MGNX
$21.07
Macrogenics
$.78
3.84%
MGNX
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.58)
Revenue:  $31.54 Mil
Thursday
Feb 25
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MGNX reports earnings?
Beat
Meet
Miss

Where is MGNX's stock price going from here?
Up
Flat
Down
Stock chart of MGNX
Analysts
Summary of analysts' recommendations for MGNX
Score
Grade
Pivots
Resistance
$23.44
$22.31
$21.69

$20.56

Support
$19.94
$18.81
$18.19
Tweet
Growth
Description
MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.
Peers
InterCeptVertex PharmaceuticalsRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbPfizerZoetisMerck & Co.Johnson & JohnsonUltragenyx Pharmaceutical